1312004 Informal Interpretation
Date
Rule
801.1
The key is date of closing.
File
Original Image File
(104.56 KB)
Displaying 3001 - 3020 of 4745
FTC Approves Final Order Settling Charges that Actavis, Inc.’s Acquisition of Warner Chilcott plc Would Be Anticompetitive in Four Current and Future Drug Markets
Date
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Actavis, Inc’s proposed acquisition of Warner Chilcott plc would reduce competition in...
Actavis, Inc. and Warner Chilcott PLC, In the Matter of
Under a settlement, the FTC required Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.The settlement protects competition in the markets for 21 current and future generic drugs, used to treat a wide range of conditions ranging from hypertension and diabetes to anxiety and attention deficit hyperactivity disorder (ADHD).
Type of Action
Administrative
Last Updated
FTC Matter/File Number
131 0152
Docket Number
C-4414
FTC Postpones Follow-On Biologics Workshop Due to Inclement Weather
Date
Due to inclement weather and the closure of the federal government for today, the Federal Trade Commission has postponed until further notice its one-day public workshop on Follow-On Biologics: Impact...
FTC Launches Redesigned FTC.gov Website
Date
The Federal Trade Commission today launched a redesigned FTC.gov website that’s easier to use and reader friendly on tablets and smart phones. Users can now sort FTC cases, early termination notices...
1312001 Informal Interpretation
Date
Rule
801.10, 801.11
Agree.
File
Original Image File
(224.09 KB)
FTC Announces Agenda for Workshop Examining Competition Issues Surrounding Biologic and Follow-on Biologic Medicines: Biosimilars and Interchangeables
Date
The Federal Trade Commission has announced the agenda for the upcoming public roundtable on “Follow-on Biologics: Impact of Recent Legislative and Regulatory Naming Proposals on Competition.” The...
FTC Staff Submits Comment to the Commission on Dental Accreditation Regarding its Proposed Standards for Dental Therapy Education Programs
Date
Federal Trade Commission staff submitted a comment to the American Dental Association’s Commission on Dental Accreditation (CODA) regarding CODA’s proposed Accreditation Standards for Dental Therapy...
Statement of Commissioner Julie Brill on The FTC at 100: Where Do We Go from Here?
Date
By
Julie Brill, Former Commissioner
RELATED TESTIMONY: Prepared Statement of the Federal Trade Commission On "The FTC At 100: Where Do We Go From Here?" (December 3, 2013)
Prepared Statement of the Federal Trade Commission On "The FTC At 100: Where Do We Go From Here?"
Date
By
Edith Ramirez, Former Chairwoman;
Julie Brill, Former Commissioner;
Maureen K. Ohlhausen, Former Commissioner;
Joshua D. Wright, Former Commissioner
Prepared Statement of the Federal Trade Commission On "The FTC At 100: Where Do We Go From Here?" – Before the Subcommittee on Commerce, Manufacturing, and Trade of the Committee on Energy and...
Statement of Chairwoman Edith Ramirez on “The FTC at 100”
Date
By
Edith Ramirez, Former Chairwoman
RELATED TESTIMONY: Prepared Statement of the Federal Trade Commission On "The FTC At 100: Where Do We Go From Here?" (December 3, 2013)
File
FTC Testifies on Its Work to Protect Consumers and Promote Competition As the Agency Approaches Its 100th Anniversary
Date
The Federal Trade Commission testified before Congress on the agency’s long track record of protecting consumers and promoting competition in the U.S. economy, as well as the agency’s ongoing work and...
FTC Approves Final Order Settling Charges that Honeywell’s Acquisition of Intermec was Anticompetitive in U.S. Market for Two-Dimensional Bar Code Scanners
Date
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Honeywell International, Inc.’s acquisition of rival scan engine manufacturer Intermec...
FTC’s 2013 Report Finds U.S. Ethanol Market Remains Unconcentrated
Date
The market for fuel ethanol in the United States is unconcentrated, with 156 firms nationwide either producing ethanol or likely to begin producing ethanol in the next 12 to 18 months, according to...
Honeywell International Inc., In the Matter of
Honeywell International Inc agreed to license patents critical to the manufacture of two-dimensional (2D) bar code scanners to settle FTC charges that it's acquisition of rival Intermed Inc would be anticompetitive. Honeywell will license its and Intermec's patents for 2D scan engines to Datalogic IPTECH s.r.l for the next 12 years.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
131 0070
1311009 Informal Interpretation
Date
Rule
801.10
Yes, you would include the cash. The parties are adjusting the purchase price to $72 million because they didn't take the cash on hand into account when they agreed on $70 million. M Verne concurs.
File
Original Image File
(90.79 KB)
Displaying 3001 - 3020 of 4745